share_log

Blueprint Medicines Q1 2024 GAAP EPS $1.40 Beats $(1.66) Estimate, Sales $96.116M Beat $80.434M Estimate

Benzinga ·  May 2 07:01

Blueprint Medicines (NASDAQ:BPMC) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $(1.66) by 184.34 percent. The company reported quarterly sales of $96.116 million which beat the analyst consensus estimate of $80.434 million by 19.50 percent. This is a 51.87 percent increase over sales of $63.287 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment